Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene-based vaccines and immunotherapeutics.

Margaret Liu1, Bruce Acres, Jean-Marc Balloul

  • 1Transgene, 11 Rue de Molsheim, 67082 Strasbourg, France. liu@transgene.fr

Proceedings of the National Academy of Sciences of the United States of America
|August 31, 2004
PubMed
Summary

DNA vaccines and viral vectors show promise for treating diseases like cancer and autoimmune disorders. Viral vectors, particularly adenoviral and modified vaccinia Ankara vectors, are being used in clinical trials for immunotherapy and cancer vaccines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of Low-Glucose Alerts and Their Impact on Continuous Glucose Monitoring Outcomes in Real-World Use of the MiniMed 780G System.

Diabetes technology & therapeutics·2026
Same author

Dissecting residual disease in spheroids reveals pan-cancer persistence signatures and a therapeutic window for oncolytic viruses.

Molecular therapy. Oncology·2026
Same author

Emerging interest of anti-integrin αvβ6 antibodies for the diagnosis and prognosis of IBD and primary sclerosing cholangitis at the gut-liver interface.

Inflammatory bowel diseases·2026
Same author

Systems serology identifies FcR-related autoantibody signatures and functions for Sjögren's syndrome.

EMBO molecular medicine·2026
Same author

MiniMed<sup><b>™</b></sup> 780G System Users Achieve Similar Glycemic Outcomes Regardless of Socioeconomic Disadvantage.

Diabetes technology & therapeutics·2026
Same author

Current status of intranasal and inhaled COVID-19 vaccines.

NPJ vaccines·2026

Area of Science:

  • Gene therapy
  • Vaccinology
  • Immunotherapy

Background:

  • DNA vaccines utilize plasmid DNA encoding proteins for prophylactic and therapeutic applications.
  • Viral vectors are being explored for enhanced gene expression compared to DNA plasmids.
  • Clinical trials are evaluating DNA and viral vector-based therapies for infectious diseases, allergies, cancer, and autoimmune diseases.

Purpose of the Study:

  • To present examples of in vivo prophylaxis and immunotherapy using DNA and viral vector-based approaches.
  • To highlight early-phase human clinical trial data for various disease models.
  • To focus on the clinical application of recombinant viral vectors for vaccine and cytokine gene transfer.

Main Methods:

  • Utilizing adenoviral vectors for in situ cytokine gene transfer into tumors for immunotherapy.

Related Experiment Videos

  • Employing adenovirus-IFN gamma (TG1042) in Phase II trials for cutaneous lymphoma.
  • Using adenovirus-IL2 (TG1024) injected into solid tumors, including melanoma.
  • Developing cancer vaccines using modified vaccinia Ankara (MVA) vectors encoding HPV E6/E7 or MUC1, coexpressed with IL-2.

    • Main Results:

    • Encouraging results have been observed in clinical trials for adenovirus-IFN gamma and adenovirus-IL2 therapies.
    • Early data from cancer vaccine programs using MVA vectors show promising outcomes.
    • Both humoral and cellular immune responses are being evaluated across different disease models.

    Conclusions:

    • Recombinant viral vectors demonstrate potential for effective cancer immunotherapy and vaccine development.
    • Adenoviral vectors show promise for cytokine gene therapy in treating cancers like lymphoma and melanoma.
    • Modified vaccinia Ankara vectors are being successfully applied in cancer vaccine strategies targeting specific tumor antigens.